Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Gilead and Galapagos deal: building on filgotinib agreement

US-based Gilead has entered into a ten-year global research and development (R&D) collaboration agreement with Belgian clinical stage biotech Galapagos, in which the former will pay $3.95bn upfront to again access to the latter’s innovative portfolio of compounds and drug discovery platform.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top